Backed by 5AM Ventures.
About the role
The Associate Director, Drug Product Development & Manufacturing, is accountable for leading drug product manufacturing activities to support Entrada’s clinical stage assets and novel pipeline programs. This role ensures successful execution of clinical manufacturing operations for parenteral drug products and partners cross-functionally to deliver uninterrupted clinical supply. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- MS in a scientific related discipline with 8 + years of biotech or pharmaceutical experience preferred
- Experience in parenteral drug product formulation development and manufacturing, with demonstrated ability to provide CDMO oversight. Direct experience with intravitreal injections is a plus
- Strong knowledge of sterile manufacturing and fill-finish operations with demonstrated experience with batch records, deviations, change controls, and tech transfer. Late-stage experience is a plus
- Demonstrated ability to lead authoring and review of technical study protocols and reports, manufacturing documentation, and regulatory documents
- Knowledge of cGMP, ICH, FDA and EMA guidelines regarding sterile drug product development and manufacturing
- Excellent verbal and written communication skills
More about this role
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex...
Browse similar: Startup jobs · Boston